These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 2485819)

  • 1. Hypothalamic compensatory mechanisms in Parkinson's disease.
    Sandyk R
    Int J Neurosci; 1989 Jan; 44(1-2):135-42. PubMed ID: 2485819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enkephalinergic mechanisms in the "compensated" phase of Parkinson's disease.
    Sandyk R
    Int J Neurosci; 1988 Oct; 42(3-4):301-3. PubMed ID: 3061957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Do compensatory processes underlie the preclinical phase of neurodegenerative disease? Insights from an animal model of parkinsonism.
    Zigmond MJ
    Neurobiol Dis; 1997; 4(3-4):247-53. PubMed ID: 9361301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The hypothalamus in Parkinson disease.
    Sandyk R; Iacono RP; Bamford CR
    Ital J Neurol Sci; 1987 Jun; 8(3):227-34. PubMed ID: 2887537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How compensation breaks down in Parkinson's disease: Insights from modeling of denervated striatum.
    Navntoft CA; Dreyer JK
    Mov Disord; 2016 Mar; 31(3):280-9. PubMed ID: 26890687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of a presymptomatic stage in a Drosophila Parkinson's disease model: Unveiling dopaminergic compensatory mechanisms.
    Molina-Mateo D; Fuenzalida-Uribe N; Hidalgo S; Molina-Fernández C; Abarca J; Zárate RV; Escandón M; Figueroa R; Tevy MF; Campusano JM
    Biochim Biophys Acta Mol Basis Dis; 2017 Nov; 1863(11):2882-2890. PubMed ID: 28716706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypothalamic-locus coeruleus mechanisms in the pathophysiology of "on-off" in L-dopa treated Parkinson's disease: a hypothesis.
    Sandyk R
    Int J Neurosci; 1989 Aug; 47(3-4):303-8. PubMed ID: 2681032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serotonin and dopamine transporter PET changes in the premotor phase of LRRK2 parkinsonism: cross-sectional studies.
    Wile DJ; Agarwal PA; Schulzer M; Mak E; Dinelle K; Shahinfard E; Vafai N; Hasegawa K; Zhang J; McKenzie J; Neilson N; Strongosky A; Uitti RJ; Guttman M; Zabetian CP; Ding YS; Adam M; Aasly J; Wszolek ZK; Farrer M; Sossi V; Stoessl AJ
    Lancet Neurol; 2017 May; 16(5):351-359. PubMed ID: 28336296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synaptic dysfunction in Parkinson's disease.
    Picconi B; Piccoli G; Calabresi P
    Adv Exp Med Biol; 2012; 970():553-72. PubMed ID: 22351072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurochemical compensation after nigrostriatal bundle injury in an animal model of preclinical parkinsonism.
    Zigmond MJ; Acheson AL; Stachowiak MK; Stricker EM
    Arch Neurol; 1984 Aug; 41(8):856-61. PubMed ID: 6147127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The implication of neuronimmunoendocrine (NIE) modulatory network in the pathophysiologic process of Parkinson's disease.
    Shen Y; Guo X; Han C; Wan F; Ma K; Guo S; Wang L; Xia Y; Liu L; Lin Z; Huang J; Xiong N; Wang T
    Cell Mol Life Sci; 2017 Oct; 74(20):3741-3768. PubMed ID: 28623510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Compensatory mechanisms in experimental and human parkinsonism: towards a dynamic approach.
    Bezard E; Gross CE
    Prog Neurobiol; 1998 Jun; 55(2):93-116. PubMed ID: 9618745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The nigrostriatal system in the presymptomatic and symptomatic stages in the MPTP monkey model: a PET, histological and biochemical study.
    Blesa J; Pifl C; Sánchez-González MA; Juri C; García-Cabezas MA; Adánez R; Iglesias E; Collantes M; Peñuelas I; Sánchez-Hernández JJ; Rodríguez-Oroz MC; Avendaño C; Hornykiewicz O; Cavada C; Obeso JA
    Neurobiol Dis; 2012 Oct; 48(1):79-91. PubMed ID: 22677034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Compensatory mechanisms in the nigrostriatal dopaminergic system in Parkinson's disease: studies in an animal model.
    Melamed E; Hefti F; Wurtman RJ
    Isr J Med Sci; 1982 Jan; 18(1):159-63. PubMed ID: 6121770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomarkers, mechanisms, and potential prevention of catecholamine neuron loss in Parkinson disease.
    Goldstein DS
    Adv Pharmacol; 2013; 68():235-72. PubMed ID: 24054148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Expression of the enzymes of dopamine synthesis in non-dopaminergic neurons: functional significance and regulation].
    Ugriumov MV
    Usp Fiziol Nauk; 2007; 38(4):3-20. PubMed ID: 18064905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Compensatory mechanisms in degenerative neurologic diseases. Insights from parkinsonism.
    Calne DB; Zigmond MJ
    Arch Neurol; 1991 Apr; 48(4):361-3. PubMed ID: 2012508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The relationship between locomotor disability, autonomic dysfunction, and the integrity of the striatal dopaminergic system in patients with multiple system atrophy, pure autonomic failure, and Parkinson's disease, studied with PET.
    Brooks DJ; Salmon EP; Mathias CJ; Quinn N; Leenders KL; Bannister R; Marsden CD; Frackowiak RS
    Brain; 1990 Oct; 113 ( Pt 5)():1539-52. PubMed ID: 2123119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversible Pharmacological Induction of Motor Symptoms in MPTP-Treated Mice at the Presymptomatic Stage of Parkinsonism: Potential Use for Early Diagnosis of Parkinson's Disease.
    Khakimova GR; Kozina EA; Kucheryanu VG; Ugrumov MV
    Mol Neurobiol; 2017 Jul; 54(5):3618-3632. PubMed ID: 27194433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-motor extranigral signs and symptoms in Parkinson's disease.
    Wolters ECh
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 3():S6-12. PubMed ID: 20083010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.